|
1
|
Lenaerts A, Barry CE III and Dartois V:
Heterogeneity in tuberculosis pathology, microenvironments and
therapeutic responses. Immunol Rev. 264:288–307. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Walsh NC, Kenney LL, Jangalwe S, Aryee KE,
Greiner DL, Brehm MA and Shultz LD: Humanized mouse models of
clinical disease. Annu Rev Pathol. 12:187–215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gong W, Liang Y, Mi J, Xue Y, Wang J, Wang
L, Zhou Y, Sun S and Wu X: A peptide-based vaccine ACP derived from
antigens of Mycobacterium tuberculosis induced Th1 response but
failed to enhance the protective efficacy of BCG in mice. Indian J
Tuberc. 69:482–495. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
WHO, . Global tuberculosis report 2024.
https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024December
17–2024
|
|
5
|
WHO, . Global tuberculosis report 2022.
https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022January
2–2024
|
|
6
|
WHO, . Global tuberculosis report 2013.
https://www.who.int/publications/i/item/9789241564656September
25–2023
|
|
7
|
WHO, . Global tuberculosis report 2016.
https://www.who.int/publications/i/item/9789241565394September
25–2023
|
|
8
|
WHO, . Global tuberculosis report 2021.
https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021January
2–2024
|
|
9
|
Uplekar M, Weil D, Lonnroth K, Jaramillo
E, Lienhardt C, Dias HM, Falzon D, Floyd K, Gargioni G, Getahun H,
et al: WHO's new End TB Strategy. Lancet. 385:1799–1801. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dye C, Glaziou P, Floyd K and Raviglione
M: Prospects for tuberculosis elimination. Annu Rev Public Health.
34:271–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lienhardt C, Lönnroth K, Menzies D,
Balasegaram M, Chakaya J, Cobelens F, Cohn J, Denkinger CM, Evans
TG, Källenius G, et al: Translational research for tuberculosis
elimination: priorities, challenges, and actions. PLoS Medicine.
13:e10019652016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pai M, Behr MA, Dowdy D, Dheda K,
Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M,
Getahun H, Menzies D and Raviglione M: Tuberculosis. Nat Rev Dis
Primers. 2:160762016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang Y, Li X, Yang Y, Xiao L, Liang Y, Mi
J, Xue Y, Gong W, Wang L, Wang J, et al: Preventive effects of
Mycobacterium tuberculosis DNA vaccines on the mouse model with
latent tuberculosis infection. Front Immunol. 14:11108432023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ruelas Castillo J, Guerrini V, Quijada D,
Karanika S, Neupane P, Urbanowski ME, Shenkoya B, Harris H, Garcia
A, Yilma A, et al: Pharmacologic inhibition of macrophage
triglyceride biosynthesis pathways does not improve Mycobacterium
tuberculosis control in infected mice. J Infect Dis. 231:1141–1149.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gong W, Liang Y, Wang J, Liu Y, Xue Y, Mi
J, Li P, Wang X, Wang L and Wu X: Prediction of Th1 and cytotoxic T
lymphocyte epitopes of Mycobacterium tuberculosis and evaluation of
their potential in the diagnosis of tuberculosis in a mouse model
and in humans. Microbiol Spectr. 10:e01438222022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Apt A and Kramnik I: Man and mouse TB:
Contradictions and solutions. Tuberculosis (Edinb). 89:195–198.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Al Shammari B, Shiomi T, Tezera L,
Bielecka MK, Workman V, Sathyamoorthy T, Mauri F, Jayasinghe SN,
Robertson BD, D'Armiento J, Friedland JS and Elkington PT: The
extracellular matrix regulates granuloma necrosis in tuberculosis.
J Infect Dis. 212:463–473. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee J, Brehm MA, Greiner D, Shultz LD and
Kornfeld H: Engrafted human cells generate adaptive immune
responses to Mycobacterium bovis BCG infection in humanized mice.
BMC Immunol. 14:532013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saunders BM and Cooper AM: Restraining
mycobacteria: Role of granulomas in mycobacterial infections.
Immunol Cell Biol. 78:334–341. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rongvaux A, Takizawa H, Strowig T,
Willinger T, Eynon EE, Flavell RA and Manz MG: Human
hemato-lymphoid system mice: Current use and future potential for
medicine. Annu Rev Immunol. 31:635–674. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stripecke R, Münz C, Schuringa JJ, Bissig
KD, Soper B, Meeham T, Yao LC, Di Santo JP, Brehm M, Rodriguez E,
et al: Innovations, challenges, and minimal information for
standardization of humanized mice. EMBO Mol Med. 12:e86622020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ning D, Deng Y, Tiedje JM and Zhou J: A
general framework for quantitatively assessing ecological
stochasticity. Proc Natl Acad Sci USA. 116:16892–16898. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brehm MA, Jouvet N, Greiner DL and Shultz
LD: Humanized mice for the study of infectious diseases. Cur Opin
Immunol. 25:428–435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Calderon VE, Valbuena G, Goez Y, Judy BM,
Huante MB, Sutjita P, Johnston RK, Estes DM, Hunter RL, Actor JK,
Cirillo JD and Endsley JJ: A humanized mouse model of tuberculosis.
PLoS One. 8:e633312013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Smart M, Behrens M, David L, Conway C and
Taneja V: Immune response to immunodominant Mycobacterium
tuberculosis antigen ESAT-6 derived peptide is HLA-haplotype
dependent. Jacobs J Allergy Immunol. 1:0022014.PubMed/NCBI
|
|
26
|
Shang S, Kats D, Cao L, Morgun E, Velluto
D, He Y, Xu Q, Wang CR and Scott EA: Induction of Mycobacterium
tuberculosis lipid-specific T cell responses by pulmonary delivery
of mycolic acid-loaded polymeric micellar nanocarriers. Front
Immunol. 9:27092018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Heuts F, Gavier-Widén D, Carow B, Juarez
J, Wigzell H and Rottenberg ME: Rottenberg: CD4(+) cell-dependent
granuloma formation in humanized mice infected with mycobacteria.
Proc Nat Acad Sci U S A. 110:6482–6487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Orme IM and Ordway DJ: Mouse and guinea
pig models of tuberculosis. Microbiol Spectr.
4:10.1128/microbiolspec.tbtb2–0002-2015. 2016. View Article : Google Scholar
|
|
29
|
Zhao J, Siddiqui S, Shang S, Bian Y,
Bagchi S, He Y and Wang CR: Mycolic acid-specific T cells protect
against Mycobacterium tuberculosis infection in a humanized
transgenic mouse model. Elife. 4:e085252015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arrey F, Löwe D, Kuhlmann S, Kaiser P,
Moura-Alves P, Krishnamoorthy G, Lozza L, Maertzdorf J, Skrahina T,
Skrahina A, et al: Humanized mouse model mimicking pathology of
human tuberculosis for in vivo evaluation of drug regimens. Front
Immunol. 10:892019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grover A, Troy A, Rowe J, Troudt JM,
Creissen E, McLean J, Banerjee P, Feuer G and Izzo AA: Humanized
NOG mice as a model for tuberculosis vaccine-induced immunity: A
comparative analysis with the mouse and guinea pig models of
tuberculosis. Immunology. 152:150–162. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bohórquez JA, Adduri S, Ansari D, John S,
Florence J, Adejare O, Singh G, Konduru NV, Jagannath C and Yi G: A
novel humanized mouse model for HIV and tuberculosis co-infection
studies. Front Immunol. 15:13950182024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Olleros ML, Chavez-Galan L, Segueni N,
Bourigault ML, Vesin D, Kruglov AA, Drutskaya MS, Bisig R, Ehlers
S, Aly S, et al: Control of mycobacterial infections in mice
expressing human tumor necrosis (TNF) but not mouse TNF. Infect
Immun. 83:3612–3623. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lepard M, Yang JX, Afkhami S, Nazli A,
Zganiacz A, Tang S, Choi MWY, Vahedi F, Deshiere A, Tremblay MJ, et
al: Comparing current and next-generation humanized mouse models
for advancing HIV and HIV/Mtb co-infection studies. Viruses.
14:19272022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hussey G, Hawkridge T and Hanekom W:
Childhood tuberculosis: Old and new vaccines. Paediatr Respir Rev.
8:148–154. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brennan MJ and Thole J: Tuberculosis
vaccines: A strategic blueprint for the next decade. Tuberculosis
(Edinb). 92:S6–S13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xing Z, Jeyanathan M and Smaill F: New
approaches to TB vaccination. Chest. 146:804–812. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gong W, Liang Y and Wu X: Animal models of
tuberculosis vaccine research: An important component in the fight
against tuberculosis. BioMed Res Int. 2020:42630792020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Andersen P and Kaufmann SH: Novel
vaccination strategies against tuberculosis. Cold Spring Harb
Perspect Med. 4:a0185232014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gong W, Liang Y, Mi J, Jia Z, Xue Y, Wang
J, Wang L, Zhou Y, Sun S and Wu X: Peptides-based vaccine MP3RT
induced protective immunity against Mycobacterium tuberculosis
infection in a humanized mouse model. Front Immunol. 12:6662902021.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dowling DJ, Scott EA, Scheid A, Bergelson
I, Joshi S, Pietrasanta C, Brightman S, Sanchez-Schmitz G, Van
Haren SD, Ninković J, et al: Toll-like receptor 8 agonist
nanoparticles mimic immunomodulating effects of the live BCG
vaccine and enhance neonatal innate and adaptive immune responses.
J Allergy Clin Immunol. 140:1339–1350. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yao Y, Lai R, Afkhami S, Haddadi S,
Zganiacz A, Vahedi F, Ashkar AA, Kaushic C, Jeyanathan M and Xing
Z: Enhancement of antituberculosis immunity in a humanized model
system by a novel virus-vectored respiratory mucosal vaccine. J
Infect Dis. 216:135–145. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Afkhami S, D'Agostino MR, Vaseghi-Shanjani
M, Lepard M, Yang JX, Lai R, Choi MWY, Chacon A, Zganiacz A,
Franken KLMC, et al: Intranasal multivalent adenoviral-vectored
vaccine protects against replicating and dormant M.tb in
conventional and humanized mice. NPJ Vaccines. 8:252023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang Y, Li J, Li D, Zhou W, Yan F and Wang
W: Humanized mouse models: A valuable platform for preclinical
evaluation of human cancer. Biotechnol Bioeng. 121:835–852. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
MacLeod AK, Coquelin KS, Huertas L,
Simeons FRC, Riley J, Casado P, Guijarro L, Casanueva R, Frame L,
Pinto EG, et al: Acceleration of infectious disease drug discovery
and development using a humanized model of drug metabolism. Proc
Natl Acad Sci U S A. 121:e23150691212024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Stutz MD, Ojaimi S, Allison C, Preston S,
Arandjelovic P, Hildebrand JM, Sandow JJ, Webb AI, Silke J,
Alexander WS and Pellegrini M: Necroptotic signaling is primed in
Mycobacterium tuberculosis-infected macrophages, but its
pathophysiological consequence in disease is restricted. Cell Death
Differ. 25:951–965. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu Y, Chen T, Zhu Y, Furey A, Lowary TL,
Chan J, Bournazos S, Ravetch JV and Achkar JM: Features and
protective efficacy of human monoclonal antibodies targeting
Mycobacterium tuberculosis arabinomannan. JCI Insight.
8:e1679602023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang F, Labani-Motlagh A, Bohorquez JA,
Moreira JD, Ansari D, Patel S, Spagnolo F, Florence J,
Vankayalapati A, Sakai T, et al: Bacteriophage therapy for the
treatment of Mycobacterium tuberculosis infections in humanized
mice. Commun Biol. 7:2942024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wienkers LC and Heath TG: Predicting in
vivo drug interactions from in vitro drug discovery data. Nat Rev
Drug Discov. 4:825–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Henderson CJ, Kapelyukh Y, Scheer N, Rode
A, McLaren AW, MacLeod AK, Lin D, Wright J, Stanley LA and Wolf CR:
An extensively humanized mouse model to predict pathways of drug
disposition and drug/drug interactions, and to facilitate design of
clinical trials. Drug Metab Dispos. 47:601–615. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nuermberger EL, Yoshimatsu T, Tyagi S,
O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR and Grosset JH:
Moxifloxacin-containing regimen greatly reduces time to culture
conversion in murine tuberculosis. Am J Respir Crit Care Med.
169:421–426. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Conde MB, Efron A, Loredo C, De Souza GR,
Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL and
Chaisson RE: Moxifloxacin-containing regimens of reduced duration
produce a stable cure in murine tuberculosis. Am J Respir Crit Care
Med. 170:1131–1134. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Conde MB, Efron A, Loredo C, De Souza GR,
Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL and
Chaisson RE: Moxifloxacin vs. ethambutol in the initial treatment
of tuberculosis: A double-blind, randomised, controlled phase II
trial. Lancet. 373:1183–1189. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gillespie SH, Crook AM, McHugh TD, Mendel
CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ and
REMoxTB Consortium: Four-month moxifloxacin-based regimens for
drug-sensitive tuberculosis. N Engl J Med. 371:1577–1587. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dorman SE, Johnson JL, Goldberg S, Muzanye
G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S,
Grosset JH, et al: Substitution of moxifloxacin for isoniazid
during intensive phase treatment of pulmonary tuberculosis. Am J
Respir Crit Care Med. 180:273–280. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tobin DM, Roca FJ, Oh SF, McFarland R,
Vickery TW, Ray JP, Ko DC, Zou Y, Bang ND, Chau TT, et al: Host
genotype-specific therapies can optimize the inflammatory response
to mycobacterial infections. Cell. 148:434–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Watson A, Li H, Ma B, Weiss R, Bendayan D,
Abramovitz L, Ben-Shalom N, Mor M, Pinko E, Bar Oz M, et al: Human
antibodies targeting a Mycobacterium transporter protein mediate
protection against tuberculosis. Nat Commun. 12:6022021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ye RG and Lu ZY: Internal medicine. 6th
edition. Beijing: Peoples Medical Publishing House; 2004
|
|
59
|
Guo M and Ho WZ: Animal models to study
Mycobacterium tuberculosis and HIV co-infection. Zoological Res.
35:163–169. 2014.
|
|
60
|
Aaron L, Saadoun D, Calatroni I, Launay O,
Mémain N, Vincent V, Marchal G, Dupont B, Bouchaud O, Valeyre D and
Lortholary O: Tuberculosis in HIV-infected patients: A
comprehensive review. Clin Microbiol Infect. 10:388–398. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nusbaum RJ, Calderon VE, Huante MB,
Sutjita P, Vijayakumar S, Lancaster KL, Hunter RL, Actor JK,
Cirillo JD, Aronson J, et al: Pulmonary tuberculosis in humanized
mice infected with HIV-1. Sci Rep. 6:215222016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Singh VK, Mishra A, Truong K, Bohorquez
JA, Sharma S, Khan A, Bracher F, Zhang K, Endsley J, Endsley M, et
al: Sirtuin2 blockade inhibits replication of Human
Immunodeficiency Virus-1 and Mycobacterium tuberculosis in
macrophages and humanized mice. bioRxiv. Oct 29–2024.(Epub ahead of
print).
|
|
63
|
Huante MB, Saito TB, Nusbaum RJ, Naqvi KF,
Chauhan S, Hunter RL, Actor JK, Rudra JS, Endsley MA, Lisinicchia
JG, Gelman BB and Endsley JJ: Small animal model of
post-chemotherapy tuberculosis relapse in the setting of HIV
co-infection. Front Cell Infect Microbiol. 10:1502020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Li T, Zhang B, Du X, Pei S, Jia Z and Zhao
Y: Recurrent pulmonary tuberculosis in China, 2005 to 2021. JAMA
Netw Open. 7:e24272662024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pawlowski A, Jansson M, Sköld M,
Rottenberg ME and Källenius G: Tuberculosis and HIV co-infection.
PLoS Pathog. 8:e10024642012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kupz A, Zedler U, Stäber M and Kaufmann
SH: A mouse model of latent tuberculosis infection to study
intervention strategies. PLoS One. 11:e01588492016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Marsden MD: Benefits and limitations of
humanized mice in HIV persistence studies. Retrovirology. 17:72020.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Shaji A, Verma A, Bhaskar A and Dwivedi
VP: BCG and beyond: Unlocking new frontiers in TB vaccine
development. Front Immunol. 16:16081042025. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yin L and Wang XJ, Chen DX, Liu XN and
Wang XJ: Humanized mouse model: A review on preclinical
applications for cancer immunotherapy. Am J Cancer Res.
10:4568–4584. 2020.PubMed/NCBI
|
|
70
|
Chandra N, Kumar D and Rao K: Systems
biology of tuberculosis. Tuberculosis (Edinb). 91:487–496. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Singh AK and Gupta UD: Animal models of
tuberculosis: Lesson learnt. Indian J Med Res. 147:456–463. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Fonseca KL, Rodrigues PNS, Olsson IAS and
Saraiva M: Experimental study of tuberculosis: From animal models
to complex cell systems and organoids. PLoS Pathog.
13:e10064212017. View Article : Google Scholar : PubMed/NCBI
|
